| 000 | 05181naaaa2201201uu 4500 | ||
|---|---|---|---|
| 001 | https://directory.doabooks.org/handle/20.500.12854/54960 | ||
| 005 | 20220220030022.0 | ||
| 020 | _abooks978-3-03921-991-9 | ||
| 020 | _a9783039219919 | ||
| 020 | _a9783039219902 | ||
| 024 | 7 |
_a10.3390/books978-3-03921-991-9 _cdoi |
|
| 041 | 0 | _aEnglish | |
| 042 | _adc | ||
| 100 | 1 |
_aDownie, Laura _4auth |
|
| 700 | 1 |
_aLawrenson, John _4auth |
|
| 245 | 1 | 0 | _aNutrition and Eye Health |
| 260 |
_bMDPI - Multidisciplinary Digital Publishing Institute _c2020 |
||
| 300 | _a1 electronic resource (242 p.) | ||
| 506 | 0 |
_aOpen Access _2star _fUnrestricted online access |
|
| 520 | _aBlindness and visual impairment impact significantly on an individual’s physical and mental well-being. Loss of vision is a global health problem, with approximately 250 million of the world’s population currently living with vision loss, of which 36 million are classified as blind. Visual impairment is more frequent in the elderly, with cataract and age-related macular degeneration (AMD) accounting for over 50% of cases globally. Oxidative stress has been strongly implicated in the pathogenesis of both conditions, and consequently the role of nutritional factors, in particular carotenoids and micronutrient antioxidants, have been investigated as possible preventative or therapeutic strategies. Dry eye syndrome (DES) is one of the most common ophthalmic conditions in the world. DES occurs where the eye does not produce enough tears and/or the tears evaporate too quicklyleading to discomfort and varying degrees of visual disturbance. There has recently been a great deal of interest in the potential for oral or topical supplementation with essential fatty acids (EFAs), specifically omega-3 and omega-6 fatty acids, as an adjunct to conventional treatments for DES. The objective of this Special Issue on ‘Nutrition and Eye Health’ is to publish papers describing the role of nutrition in maintaining eye health and the use of nutritional interventions to prevent or treat ocular disease. A particular (but not exclusive) emphasis will be on papers (reviews and/or clinical or experimental studies) relating to cataract, AMD and DES. | ||
| 540 |
_aCreative Commons _fhttps://creativecommons.org/licenses/by-nc-nd/4.0/ _2cc _4https://creativecommons.org/licenses/by-nc-nd/4.0/ |
||
| 546 | _aEnglish | ||
| 653 | _apolyphenols | ||
| 653 | _an/a | ||
| 653 | _acrocin | ||
| 653 | _achyrsin | ||
| 653 | _aglaucoma | ||
| 653 | _adietary assessment | ||
| 653 | _aphotoreceptor degeneration | ||
| 653 | _adry eye | ||
| 653 | _aRR-zeaxanthin | ||
| 653 | _anutritional supplements | ||
| 653 | _adrug discovery | ||
| 653 | _acorneal neovascularization (CNV) | ||
| 653 | _aAMD | ||
| 653 | _adietary antioxidants | ||
| 653 | _amicronutrients | ||
| 653 | _aage-related macular degeneration | ||
| 653 | _apreclinical models | ||
| 653 | _alenses | ||
| 653 | _amicrovascular lesions | ||
| 653 | _acyclooxigenase-2 (COX-2) | ||
| 653 | _aangiogenesis | ||
| 653 | _afish oil | ||
| 653 | _amacrophage | ||
| 653 | _aanti-oxidant | ||
| 653 | _avascular endothelial growth factor (VEGF) | ||
| 653 | _arosmarinic acid | ||
| 653 | _avisual cycle | ||
| 653 | _adiabetic retinopathy | ||
| 653 | _alutein | ||
| 653 | _agut-retina axis | ||
| 653 | _alight damage | ||
| 653 | _acrocetin | ||
| 653 | _asupplements | ||
| 653 | _aclinical practice guidelines | ||
| 653 | _anutrition | ||
| 653 | _alight | ||
| 653 | _aeye disease | ||
| 653 | _adietary habits | ||
| 653 | _aflavonoids | ||
| 653 | _aphytoconstituents | ||
| 653 | _asaffron | ||
| 653 | _acarotenoids | ||
| 653 | _afatty acid | ||
| 653 | _aelectroretinography | ||
| 653 | _alens | ||
| 653 | _aadvanced glycation end products | ||
| 653 | _ainterleukin-1? (IL-1?) | ||
| 653 | _amesozeaxanthin (RS zeaxanthin) | ||
| 653 | _aendoplasmic reticulum stress | ||
| 653 | _aomega-3 polyunsaturated fatty acids | ||
| 653 | _aclinical survey | ||
| 653 | _acorneal chemical burn | ||
| 653 | _areduced glutathione | ||
| 653 | _aomega-3 | ||
| 653 | _aAGREE II | ||
| 653 | _aretina | ||
| 653 | _ainflammation | ||
| 653 | _aanti-inflammatory | ||
| 653 | _aretinal pigment epithelium | ||
| 653 | _adiet | ||
| 653 | _aLactobacillus paracasei KW3110 | ||
| 653 | _aCrocus Sativus L. | ||
| 653 | _asaponins | ||
| 653 | _acataract | ||
| 653 | _aCODS | ||
| 653 | _aneoangiogenesis | ||
| 653 | _aestrogen-deficient rats | ||
| 653 | _afood frequency questionnaire | ||
| 653 | _agut microbiota | ||
| 653 | _aantioxidant supplements | ||
| 653 | _asinapic acid | ||
| 653 | _apersonalised medicine | ||
| 653 | _asystematic reviews | ||
| 653 | _anuclear factor-kappaB (NF-?B) | ||
| 653 | _adiabetes | ||
| 653 | _aCucurbita argyrosperma | ||
| 653 | _aoxidative stress | ||
| 653 | _aendoplasmic reticulum | ||
| 856 | 4 | 0 |
_awww.oapen.org _uhttps://www.mdpi.com/books/pdfview/book/1918 _70 _zDOAB: download the publication |
| 856 | 4 | 0 |
_awww.oapen.org _uhttps://directory.doabooks.org/handle/20.500.12854/54960 _70 _zDOAB: description of the publication |
| 999 |
_c60965 _d60965 |
||